Kornimate/medical-research-clean huggingface dataset:
prevalence of replication of human herpes virus 6 (hhv6) in blood and skin during exanthemia, in patients with hemopathy. is there a correlation with the etiology of the exanthema?

Conditions: HHV6; Exanthema; Hemopathy

Summary: to look for the replication of hhv6 by pcr in the skin, in these patients with haemopathies presenting an exanthema. this will make it possible to evaluate the prevalence of the positivity of this pcr in the skin. then the investigator can investigate whether there is an association between the positivity of hhv6 pcr in the blood and / or skin and the viral etiology of the exanthema. if this association exists, it will make it possible to improve the diagnosis in the context of the exanthema and thus to improve the therapeutic management of these patients.


Eligibility criteria:
inclusion criteria: * supported for any type of hemopathy. * allograft, autografted or ungrafted haematopoietic stem cells * having presented an exanthema during hospitalization, for which a cutaneous biopsy had been performed * having had a blood test of the hhv6 virus by pcr at least within the previous 40 days or following the rash. * age greater than or equal to 18 years * patient informed of the protocol by post, not having refused within one month of sending the said courier. exclusion criteria: * patient who refused the search. * patient whose hhv6 pcr in the blood was carried out at a distance of more than 40 days from the skin biopsy.
impact of sleep quality on outcomes after cardiac surgery

Conditions: Sleep; Atrial Fibrillation; Delirium, Postoperative; Complications, Postoperative

Summary: sleep is a basic human need and is essential for good quality of life, good health. in fact, humans spend one third of their life time in sleeping or attempting to do so. however, sleep is not given due importance in intensive care unit (icu)'s, although it is critical in healing process. patient's usually get admitted to the hospital few days prior to the surgery, for complete evaluation, depending on the procedure planned. hospital environment being, an entirely new place for inpatients, will invariably affect their sleep. sleep deprivation is one of the major sources of anxiety and stress in all the patients during icu stay. this means that most of patients are sleep deprived, by the time they are admitted to icu. the negative effects of sleep deprivation include postoperative brain dysfunction like inattention, restlessness, hallucinations, agitation, aggressiveness. the degree of cognitive impairment may range from subtle derangements in attention, reason, clarity of thought and capacity of decision making to confusion and delirium. sleep deprivation can also induce hypertension, fatigue, metabolic disorders, cerebrovascular and cardiovascular disease


Eligibility criteria:
inclusion criteria: * adult cardiac surgical patients aged above 18years undergoing elective cardiac surgery exclusion criteria: * not willing to give consent * preoperative sleep medications use * preoperative psychological disorders, on mechanical ventilation for \>12hrs, dementia, cerebrovascular accident

Keywords: cardiac surgery sleep quality
study of conventional laparoscopic hysterectomy versus robot-assisted laparoscopic hysterectomy at a teaching institution

Conditions: Menorrhagia; Dysfunctional Uterine Bleeding; Leiomyoma; Pelvic Pain; Endometriosis

Summary: approximately 600,000 women undergo hysterectomy each year in the united states, of which 12% are laparoscopic. the most common indications for hysterectomy are: symptomatic uterine leiomyomas (40.7%), endometriosis (17.7%), and prolapse (14.5%). the first total laparoscopic hysterectomy was performed by reich et al in 1988. many studies have proven that laparoscopic hysterectomy is associated with lower preoperative morbidity, shorter hospital stay, and shorter recovery times than abdominal hysterectomy. the literature has also shown the complication rates for laparoscopic cases are similar to open procedures in the hands of an experienced laparoscopic surgeon. the american congress of obstetricians and gynecologists committee on gynecologic practice state that laparoscopic hysterectomy is an alternative to abdominal hysterectomy for those patients in whom vaginal hysterectomy is not indicated or feasible. the acog committee on gynecologic practice site multiple advantages of laparoscopic hysterectomy to abdominal hysterectomy including faster recovery, shorter hospital stay, less blood loss, and fewer abdominal wall/wound infections. despite the recommendations of acog for a more minimally invasive approach, 66% of all hysterectomies are performed abdominally. key reasons for the lag in utilization of laparoscopic techniques are the technical obstacles of performing minimally invasive hysterectomies. robotic technology has emerged as a means to decrease the learning curve and increase the availability of minimally invasive surgery to patients. a current review of the literature reveals no randomized trials evaluating the efficacy of conventional laparoscopic hysterectomy vs. robot-assisted laparoscopic hysterectomy. the investigator's aim is to address this void. the primary objective of this study is to determine whether robot-assisted laparoscopic hysterectomy is equivalent to conventional laparoscopic hysterectomy with respect to operative time, blood loss, and hospital stay. the investigator's secondary objective was to assess the cost, morbidity, and mortality of each procedure.

see above

Eligibility criteria:
inclusion criteria: * individuals recruited into this study will be patients presenting to the urogynecology and minimally invasive surgical group for consultation for hysterectomy. exclusion criteria:individuals who are not candidates for laparoscopic surgery * medical condition that does not allow pneumoperitoneum * medical condition that does not allow proper ventilation during anesthesia * uterine size precluding access to the uterine artery * pelvic organ prolapse amendable to a vaginal approach

Keywords: hysterectomy laparoscopy robotics
topotecan plus paclitaxel and carboplatin in the initial treatment of advanced ovarian and primary peritoneal carcinoma

Conditions: Ovary Cancer

Summary: the purpose of this study is to evaluate the feasibility and toxicity of the combination of paclitaxel, carboplatin, and topotecan in patients with previously untreated, stage iii or iv epithelial ovarian carcinoma or primary peritoneal carcinoma. we will also make a preliminary evaluation of the efficacy of this three drug regimen in the initial treatment of these patients.

upon determination of eligibility, all patients will be receive: paclitaxel + carboplatin + topotecan a maximum of six courses of chemotherapy will be given at 21 day intervals

Eligibility criteria:
inclusion criteria: to be included in this study, you must meet the following criteria: * epithelial ovarian carcinoma or primary peritoneal carcinoma * willing to consider second-look surgery to evaluate response if necessary * no previous treatment with chemotherapy or radiation therapy * ability to perform activities of daily living with minimal assistance * adequate bone marrow, liver and kidney function * written informed consent exclusion criteria: you cannot participate in this study if any of the following apply to you: * age \< 18 years * brain metastases * recent history of significant heart disease within 6 months * other significant medical conditions please note: there are additional inclusion/exclusion criteria. the study center will determine if you meet all of the criteria. if you do not qualify for the trial, study personnel will explain the reasons. if you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

Keywords: ovary cancer
continuous finger-cuff arterial pressure monitoring and intraoperative hypotension during non-cardiac surgery: the randomized detect ii trial

Conditions: Intraoperative Hypotension

Summary: this is a randomized trial (1) investigating whether continuous finger-cuff - compared to intermittent oscillometric - arterial pressure monitoring reduces the amount of intraoperative hypotension (specifically, from the start of induction of general anesthesia until the end of surgery) in low-to-moderate risk patients having elective non-cardiac surgery.

not provided

Eligibility criteria:
we will include three types of patients: 1. patients scheduled for ambulatory (outpatient) elective non-cardiac surgery expected to last ≥30 minutes 2. low-risk patients (asa i+ii) having inpatient elective non-cardiac surgery expected to last ≥60 minutes 3. moderate-risk patients (asa iii) having inpatient elective non-cardiac surgery expected to last ≥60 minutes we will only include patients who are 18 years or older; who will have general anesthesia; and in whom intermittent arterial pressure monitoring with upper-arm cuff oscillometry is planned. patients that meet one or more of the following exclusion criteria cannot participate in the trial: * emergency surgery * patients on renal replacement therapy * contraindications for finger-cuff monitoring (e.g., raynaud disease)

Keywords: finger-cuff blood pressure intraoperative hypotension
intravenous(iv) vs. erector spinae plane blocks in cardiac surgery

Conditions: Erector Spinae Plane Block; Pain Control; Post-Operative Pain, Chronic

Summary: interfascial plane blocks have been developed for analgesia, among which the erector spinae plane (esp) has gained popularity. the esp block has been hypothesized to provide truncal analgesia by spread of local anesthetic into the paravertebral space. recent studies have contested this idea showing unreliability in the spread of the local anesthetic into the paravertebral space.

post-operative pain is a significant issue following open heart surgeries and poorly controlled pain can result in significant cardiorespiratory morbidity. many patients suffer pain both at rest (49%) and on movement (62%) following open heart surgeries via sternotomy and adequate pain management requires closer re-assessment and treatment. the intensity of pain is noted to be higher in the first 48 hours post surgery and hence modalities to control pain may make the greatest difference in the first 2 days after surgery. enhanced recovery pathways utilizing multimodal analgesia have shown significant analgesic and opioid sparing benefit while minimizing icu and length of hospital stays. some multimodal regimens have also incorporated regional blocks but the optimal analgesic regimen remains elusive. the esp block has been hypothesized to provide truncal anesthesia by spread of local anesthetic into the paravertebral space, but recent studies contest this idea. bilateral paravertebral blocks can result in higher than acceptable levels of local anesthetic in both cardiac and non-cardiac surgical patients and this may be true following bilateral erector spinae plane (esp) as well. hence, the pharmacokinetic profile of administered local anesthetics is necessary given the lack of information about the local anesthetic systemic levels following bilateral esp.

Eligibility criteria:
inclusion criteria: * undergoing elective cardiac surgery for coronary artery bypass graft (cabg) or valve surgery via sternotomy. * english speaking exclusion criteria: * emergency surgery * allergy to medications (ie lidocaine) * bmi less than 20 or greater than 50 * major liver or kidney dysfunction or other pre-existing major organ dysfunction * revision cardiac surgery * surgery via thoracotomy * off-pump coronary artery bypass * narcotic dependent (opioid intake morphine equivalents greater than 10mg/day for more than 3 months * chronic pain (ie fibromyalgia) * significant central nervous system or respiratory disease * hematological disorders or de-ranged coagulation parameters * psychiatric illness that impedes subject from providing informed consent * pre-operative neurological deficits * language barrier * inability to provide informed consent * prisoner status * pregnancy
homeopathic medication and nutritional oriented diet to treat overweight pregnant women with mental disorder

Conditions: Overweight; Pregnancy; Mental Disorder

Summary: the purpose of this study is to evaluate the efficacy of homeopathic treatment in pregnant women with overweight and class i obesity with suspicion of a mental disorder.

the weight gain during pregnancy has been reported as an important factor of being overweight after delivery and comorbidities. there are a lot of restrictions to treat pregnant women due to fetus development. homeopathy presents itself as an integrative medicine that could treat with less collateral effects improving general health. the investigators are going to test the effects of homeopathy.

Eligibility criteria:
inclusion criteria: * pregnant women with less than 28 weeks, * bmi from 26 to 35 kg/ m2, * srq-20 positive. exclusion criteria: * diabetes * cardiopathies * hypertension * nephropathies * psychiatric treatment * drug users * pulmonary chronic disease * suicidal ideas * no eating (appetites) * problems of bmi measurements (disabled people) * concomitant homeopathic treatment * people who are looking for just 1 medical appointment

Keywords: homeopathy overweight obesity mental disorder pregnancy overweight pregnant women with suspicious mental disorder
radioiodine dosimetry protocol for thyroid cancer metastases

Conditions: Thyroid Carcinoma; Metastatic Sites Lung Bone Nodal

Summary: the main purpose of the study is to establish a relationship between the administered activity of the radioiodine and absorbed dose in the tumor sites.

study design - the assessment of patients with multiple tumour sites with metastatic thyroid cancer to correlate the administered activity to absorbed dose. patients will receive the standard therapy dose of 5.5 gbq as per the hospital policy and there will be no change for the protocol purpose.

Eligibility criteria:
inclusion criteria: * age above 18 * histological confirmation of the differentiated thyroid carcinoma available * who performance score 0-2 * metastatic sites lung and/or bone and/or nodal (radiologically measurable disease \> 1 cm) * life expectancy \> 6 months * patient has undergone total/near total thyroidectomy * no past history of sensitivity/reaction to 1311 exclusion criteria: * non iodine concentrating tumours * received chemotherapy or radiotherapy in 6 weeks * pregnant or breast feeding patients * iodine contrast injection in last 3 months

Keywords: radioiodine differentiated thyroid cancers dosimetry metastases
efficacy and safety of semaglutide once-weekly versus placebo in drug-naïve subjects with type 2 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted globally. the aim of this trial is to investigate efficacy and safety of semaglutide once-weekly versus placebo in drug-naïve subjects with type 2 diabetes. (sustain™ 1-monotherapy).


Eligibility criteria:
inclusion criteria: - for japan only: male or female, age above or equal to 20 years at the time of signing inform consent - subjects diagnosed with type 2 diabetes and treated with diet and exercise for at least 30 days before screening - hba1c 7.0 - 10.0 % (53 - 86 mmol/mol) (both inclusive) exclusion criteria: - female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice) throughout the trial including the 5 week follow-up period. united kingdom: adequate contraceptive measures are defined as established use of oral, injected or implanted hormonal methods of contraception, placement of an intrauterine device or intrauterine system, barrier methods of contraception (condom or occlusive cap with spermicidal foam/gel/film/cream/suppository), male sterilisation (where partner is sole partner of subject), or true abstinence (when in line with preferred and usual lifestyle) - any chronic disorder or severe disease which, in the opinion of the investigator, might jeopardise subject's safety or compliance with the protocol - treatment with any glucose lowering agent(s) in a period of 90 days prior to screening. an exception is short-term treatment (no longer than 7 days in total) with insulin in connection with inter-current illness - history of chronic or idiopathic acute pancreatitis - screening calcitonin value above or equal to 50 ng/l (pg/ml) - personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (men 2) - impaired renal function defined as egfr (estimated glomerular filtration rate ) below 30 ml/min/1.73 m\^2 per modification of diet in renal disease (mdrd) formula (4 variable version) - acute coronary or cerebrovascular event within 90 days before randomisation - heart failure, new york heart association class iv
variability of healthy people and people after stroke results in the nine hole peg test

Conditions: Motor Activity

Summary: main aim of the study is to find out how many attempts of each subtest in the nine hole peg test should be done in clinical practice during testing people after stroke who are 20-64 years old.


Eligibility criteria:
inclusion criteria: * age: 20-64 years (inclusive) * hospitalized patient in rehabilitation centre kladruby * women and men with czech as their mother tongue * signed informed consent * ability to maintain a stable sitting position for the duration necessary for testing * comprehension of verbal instructions and recordings for the nine hole peg test exclusion criteria: * inability to successfully complete a pilot attempt of the nine hole peg test using the right and left hand * severe spastic paresis of the upper limb, which would make the test impossible * plegia of the upper limb * failure to complete the test to visual or hearing impairment * inability to understand verbal instructions * inability to maintain attention during testing * severe attention deficit disorder * neglect syndrome * fatigue * external factors that prevent the complete completion of the test

Keywords: nine hole peg test stroke czech extended version of manual for the nine hole peg test
lymphodepletion and anti-pd-1 blockade to reduce relapse in aml patient not eligible for transplant

Conditions: Acute Myeloid Leukemia

Summary: aml is the most common acute leukemia in adults. most patients can undergo allogeneic stem cell transplantation as a possible cure; however, many patients are not candidates for allogeneic transplant due to age, overall health, psychosocial factors, and/or lack of available donors. therefore, these patients are unable to receive the therapeutic benefits of the "graft-versus-leukemia" effect of donor immune cells. the aim of this study is to hopefully break immune tolerance to aml cells to provide better outcomes in patients with non-favorable risk aml.

non-favorable risk aml patients will undergo a preparative regimen of lymphodepletion of flu/mel followed by autologous transplantation. anti-pd-1 therapy of pembrolizumab will begin on day +1 following stem cell transplantation and will be administered every 3 weeks for a total of 8 doses. according to the literature, the risk of 2-year relapse is estimated to be 60-80% in patients with non-favorable risk aml in cr-1. with this protocol, investigators hypothesize that following lymphodepleting chemotherapy and pembrolizumab, the 2-year relapse risk will decrease to less than or equal to 35%. the one-sided wald test at 5% significance level will be used to test the hypothesis. the size of 20 patients yields the power of 90.5% assuming that the actual 2-year leukemia-free survival is 60%.

Eligibility criteria:
inclusion criteria: * non-favorable risk aml * in cr-1 or subsequent cr * completed at least one cycle of consolidation chemotherapy * collection of at least 2x106/kg cd34+ cells * kps of 70% or greater exclusion criteria: * received investigational agent within 4 weeks of first dose * prior chemotherapy, radiation therapy within 2 weeks of first dose * hypersensitivity to pembrolizumab or any of its excipients * received prior therapy with anti-pd-1, anti-pd-l1, or anti-pd-l2 agent

Keywords: aml
study evaluating efficacy / safety of etanercept + methotrexate compared to usual treatment in moderate ra subjects

Conditions: Rheumatoid Arthritis

Summary: to assess comparative radiographic efficacy, clinical efficacy and safety of etanercept (etn) + methotrexate (mtx) with usual disease-modifying anti-rheumatic drug (dmard) treatment in subjects with moderate ra who were treated with mtx monotherapy, but continue to have moderate disease activity.


Eligibility criteria:
inclusion criteria: * meet the 1987 acr revised criteria for rheumatoid arthritis. * documented evidence, confirmed by a blinded 3rd party assessor, of at least one erosion observed by x-ray at randomization based on x-ray taken at the screening visit. * have received mtx as stable dose for 28 days prior to the screening visit. exclusion criteria: * previous treatment with etn, infliximab, adalimumab, other tumor necrosis factor (tnf) -a inhibitors, anakinra or other biological agents. * receipt of any dmard, other than mtx, within 28 days before screening.

Keywords: moderate rheumatoid arthritis
postmarketing surveillance study of atrovent® inhalation solution in chronic obstructive pulmonary disease

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: to obtain further information on the tolerability and efficacy of atrovent® 500µg/2ml inhalation solution in the treatment of chronic obstructive pulmonary disease under conditions of daily practice


Eligibility criteria:
inclusion criteria: * patients of both genders, older than 40 years,who suffer from chronic obstructive pulmonary disease * only patients who had not been treated with atrovent® within the last year were to be considered for inclusion exclusion criteria: * contraindication listed in the instructions for use/summary of product characteristics for atrovent® 500µg/2ml inhalation solution * patients who exhibited adverse drug reactions
continuous positive airway pressure (cpap) mode impact on clinical blood arterial pressure

Conditions: Obstructive Sleep Apnea Syndrome

Summary: background: continuous positive airway pressure (cpap) is the first line therapy for obstructive sleep apnea syndrome (osas). two positive airway pressure (pap) modalities can be used: fixed pressure, in which the effective pressure is set and kept constant all night, and auto cpap devices where the positive pressure changes during the night depend on patient's requirements. hypothesis: pressure variations associated with autocpap functioning can lead to sleep fragmentation and alterations in sleep structure. this can limit blood pressure dipping during sleep and then impact clinical blood pressure reduction. main objective: to compare in a randomized controlled trial 4 months clinical blood pressure (bp) evolution depending on cpap mode: fixed pressure versus autocpap. secondary outcomes: evolution of arterial stiffness, biological parameters, quality of life and symptoms. methods: patients will be randomised depending on cpap mode. baseline and 4 months evaluation will include: 24-h ambulatory blood pressure monitoring, clinical bp measurements and carotid-to-femoral pulse wave velocity (pwv). patients will also complete quality of life and symptoms questionnaires. 2 interim analysis will be carried out when 150 and 220 patients respectively will have completed the study. the peto's method will be used to correct the p-values.


Eligibility criteria:
inclusion criteria: * age between 18 and 80 years * patients who gave written informed consent * patients who subscribed a social insurance * saos patients who need cpap treatment. exclusion criteria: * cardiac failure known and treated * central apnea syndrome * patients who stopped cpap treatment in the previous year * pregnant women * patients under guardianship * imprisoned patients, patients in hospital * patients included in an other clinical study

Keywords: obstructive sleep apnea syndrome blood pressure continuous positive airway pressure